OMG! Tuesday 28 June: Summary of last week’s newsletter

Share On Facebook
share on Linkedin

The OMG newsletter recommends at least 15 companies each month, using the writers’ experience of small caps to give you a winning edge. Last week they wrote about Ondo Insurance TechAppreciate Group, ReNeuron Group and Seeen. Read about these Opportunities 4 Material Gains!


Mid-week Tips

Two for the Price of One

Ondo Insurance Tech (ONDO) the Mkt cap has fallen to £4m at 5.75p having listed in March 2020 at 12p.  Since the IPO three announcements have reported progress being made with Insurance company trials and an industry report upgrading the Leakbot’s value. We would expect   further announcements as the commercialization develops.  A factor upsetting the price could be that its major shareholder with 19% and lender Homeserve are being acquired. The Homeserve shares are however locked in for two years, but it could open the door for a strategic investor.

We estimate net cash is £2.2m which should be sufficient for the business to gain commercial traction so it’s worth buying.

Appreciate Group (App) 26.5p (26p-27p) Mkt Cap: £48.5m are unchanged ahead of finals this Tuesday 28th June.  The Trading Update stated improved revenue to £205m from £186m and that profits would be ahead of market expectations.  The recovery is from the closure of many non-essential stores during lock-down making it a struggled to redeem gift vouchers.  Sales have recovered to 90% of pre-lockdown levels and vouchers could become a more popular as they act as an inflation hedge rising prices of the underlying gifts. The new team’s focus is on Digital and Corporate strategy, where the differentiated proposition is particularly strong.

We anticipate a return to profits of around £7m for a P/E of 9x and a 1.5p Dividend would make a yield of 5%. Harder times may help accelerate from recovery to growth. Buy.


Results Preview

ReNeuron Group (LSE: RENE) 28.5p (28p/29p) Monday  4th July

ReNeuron has been on the cutting edge of Proprietary Stem Cell technologies for years  but blunted by little success are focusing on Exosome Technologies. (Exosomes are nano‐sized and serve as mediators for cell‐to‐cell communication). Its primary objective is the development of novel stem cell-based technologies targeting areas of significant unmet or poorly met medical need. They provide some of the bio- spades that are needed for the drug discovery process. Finals for the year end March 2022 are reported a week on Monday. A drug discovery company can go a long way without discovering  drugs, it seems  –its near the  year’s  low and  could make a  speculative buy.

Seeen (LSE: SEEN) 13p (12p/14p)  Mkt Cap  £7m  Thursday 30th  June

The strategic focus is commercialisation of existing technologies with its B2B clients. SEEEN aim to accelerate the roll-out with new customer wins and are aiming for break-even for the next  year-end.The last figures for the six months to June reported an increase in Revenue to $5.1m with a Loss before Tax of $1.5m with cash down to $3.9m. Theses finals to December 2021 are likely to show a decline in losses but given strict cost control and some new orders there could be sufficient funding, although further funding maybe helpful  to accelerate sales. Sumitomo is a Fortune 500 company, who are a 4.6% shareholders and commercial partner. Other shareholders include Canaccord 9.5%, Rathbone 3.5%, Gresham House 13.3%, and Water Intelligence with 7.9%. Around 60% of the shares are held by institutional investors, directors, and former directors. New client wins could add excitement.



SYS – 26.5p- Worth buying

BGO – 144p-A deal bounce

SEE – 6.9p – More contracts

VANL – 41.5p – Transpennine framework

AGL – 103p – Clinical labs business builds

TWD – 49.5p – Revenues lower but expected profit on track

LOAD – 195p – Northbridge becomes Crestchic

RLE – 35.5p – Raised quarterly dividend



This weeks red flag event are UK and US GDP. State of the economy speeches from US, UK and EU central bankers  can be expected to try smooth over the  larger pitfalls as we struggle along the path  of this  business cycle.


OMG!  Opportunity for Massive Gains is a Premium Newsletter on ADVFN with two reports each week written by experienced small cap specialists. To get trips like this every week, sign up here.


CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

Do you want to write for our Newspaper? Get in touch:

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |

V: D: 20230528 23:33:00